C. Platerzyberk et al., ANTI-CD5 THERAPY DECREASES SEVERITY OF ESTABLISHED DISEASE IN COLLAGEN TYPE II-INDUCED ARTHRITIS IN DBA 1 MICE/, Clinical and experimental immunology, 98(3), 1994, pp. 442-447
Collagen-induced arthritis has been widely used as an animal model of
rheumatoid arthritis. We have used this model with a view to determini
ng potential therapeutic targets for the treatment of human disease. T
o do this we have attempted to modulate the progression of established
arthritis over a 10-day time period following the first appearance of
disease, by i.p, injection of one of three different MoAbs. These con
sist of a rat IgG2a specific for the CD5 antigen expressed on all T ce
lls and a subpopulation of B cells, a mouse IgG2b recognizing the CD72
antigen, and a rat IgM specific for the B220 molecule, CD72 and B220
both being expressed on all B cells. None of the three MoAbs had deple
ting activity in vivo. The progression of arthritis was monitored both
clinically, and histologically. The effects of treatment with anti-CD
S and anti-CD72 antibodies were compared with control antibodies of th
e same species class and subclass. In the case of anti-B220 antibodies
, the effects of treatment were compared with administration of PBS. O
f these MoAbs, only treatment with anti-CDS resulted in disease amelio
ration with significant decrease in disease severity in 60% of the ani
mals. These changes became apparent 6 days after initiation of treatme
nt. There were no significant differences in serum levels of IgG antib
odies to native bovine collagen type II between the groups of treated
and control mice. Possible mechanisms underlying the modification of d
isease expression following treatment with anti-CDS MoAb are discussed
.